Douglas Lowy and John Schiller received the 2017 Lasker-DeBakey Clinical Medical Research Award on Sept. 15 for research that led to development of the human papillomavirus vaccine.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
